FAXC

Summary

FAXC (failed axon connections homolog, metaxin like GST domain containing, HGNC:20742) is a protein-coding gene on chromosome 6q16.2, encoding Failed axon connections homolog (Q5TGI0). May play a role in axonal development.

Predicted to be located in membrane. Predicted to be active in cytoplasm.

Source: NCBI Gene 84553 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 59 total
• MANE Select transcript: NM_032511

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20742
Approved symbol	FAXC
Name	failed axon connections homolog, metaxin like GST domain containing
Location	6q16.2
Locus type	gene with protein product
Status	Approved
Aliases	MGC2817, dJ273F20
Ensembl gene	ENSG00000146267
Ensembl biotype	protein_coding
Entrez	84553

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000389677, ENST00000461803, ENST00000480148, ENST00000538471

RefSeq mRNA: 5 — MANE Select: NM_032511 NM_001346530, NM_001346531, NM_001346532, NM_001346533, NM_032511

CCDS: CCDS34500

Canonical transcript exons

ENST00000389677 — 6 exons

Exon	Start	End
ENSE00000974800	99323444	99323667
ENSE00001124929	99349107	99349674
ENSE00001911139	99271168	99281453
ENSE00003556156	99291704	99291820
ENSE00003612737	99342898	99343033
ENSE00003655139	99333351	99333547

Expression profiles

Bgee: expression breadth ubiquitous, 188 present calls, max score 95.79.

FANTOM5 (CAGE): breadth broad, TPM avg 1.7134 / max 53.4280, expressed in 664 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
74788	0.6074	327
74792	0.4385	207
74791	0.2588	133
74790	0.2300	130
74789	0.1185	42
74787	0.0602	18

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	95.79	gold quality
ganglionic eminence	UBERON:0004023	93.87	gold quality
prefrontal cortex	UBERON:0000451	90.34	gold quality
ventricular zone	UBERON:0003053	90.23	gold quality
lower esophagus muscularis layer	UBERON:0035833	89.84	gold quality
lower esophagus	UBERON:0013473	89.80	gold quality
muscle layer of sigmoid colon	UBERON:0035805	89.46	gold quality
Brodmann (1909) area 9	UBERON:0013540	88.65	gold quality
adenohypophysis	UBERON:0002196	88.02	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	87.95	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.66	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	87.50	gold quality
right frontal lobe	UBERON:0002810	87.47	gold quality
frontal cortex	UBERON:0001870	87.15	gold quality
neocortex	UBERON:0001950	86.88	gold quality
pituitary gland	UBERON:0000007	86.00	gold quality
anterior cingulate cortex	UBERON:0009835	85.90	gold quality
mucosa of stomach	UBERON:0001199	84.98	gold quality
cerebral cortex	UBERON:0000956	84.69	gold quality
hypothalamus	UBERON:0001898	84.30	gold quality
smooth muscle tissue	UBERON:0001135	84.23	gold quality
nucleus accumbens	UBERON:0001882	83.40	gold quality
forebrain	UBERON:0001890	83.32	gold quality
cerebellar cortex	UBERON:0002129	83.27	gold quality
cerebellar hemisphere	UBERON:0002245	83.26	gold quality
cerebellum	UBERON:0002037	82.95	gold quality
amygdala	UBERON:0001876	82.94	gold quality
islet of Langerhans	UBERON:0000006	82.88	gold quality
brain	UBERON:0000955	82.85	gold quality
right hemisphere of cerebellum	UBERON:0014890	82.60	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.15

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

330 targeting FAXC, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787

Cross-species orthologs

16 orthologs

Organism	Symbol	Gene ID
danio_rerio	faxca	ENSDARG00000075956
danio_rerio	faxcb	ENSDARG00000078981
mus_musculus	Faxc	ENSMUSG00000028246
rattus_norvegicus	Faxc	ENSRNOG00000010106
drosophila_melanogaster	fax	FBGN0014163
caenorhabditis_elegans		WBGENE00000412
caenorhabditis_elegans		WBGENE00008296
caenorhabditis_elegans		WBGENE00008297
caenorhabditis_elegans		WBGENE00010470
caenorhabditis_elegans		WBGENE00010471
caenorhabditis_elegans		WBGENE00010472
caenorhabditis_elegans		WBGENE00010473
caenorhabditis_elegans		WBGENE00012987
caenorhabditis_elegans		WBGENE00013266
caenorhabditis_elegans		WBGENE00016116
caenorhabditis_elegans	F53G12.9	WBGENE00018774

Paralogs (3): MTX2 (ENSG00000128654), MTX1 (ENSG00000173171), MTX3 (ENSG00000177034)

Protein

Protein identifiers

Failed axon connections homolog — Q5TGI0 (reviewed: Q5TGI0)

All UniProt accessions (1): Q5TGI0

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in axonal development.

Subcellular location. Membrane.

Similarity. Belongs to the FAX family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q5TGI0-1	1	yes
Q5TGI0-2	2

RefSeq proteins (5): NP_001333459, NP_001333460, NP_001333461, NP_001333462, NP_115900* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR012336	Thioredoxin-like_fold	Domain
IPR026928	FAX/IsoI-like	Family
IPR033468	Metaxin_GST	Domain
IPR036249	Thioredoxin-like_sf	Homologous_superfamily
IPR036282	Glutathione-S-Trfase_C_sf	Homologous_superfamily
IPR040079	Glutathione_S-Trfase	Family
IPR045796	FAXC_N	Domain
IPR050931	Mito_Protein_Transport_Metaxin	Family

Pfam: PF17171, PF17172, PF19333

UniProt features (4 total): chain 1, transmembrane region 1, region of interest 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5TGI0-F1	74.89	0.54

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 118 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, GGCNKCCATNK_UNKNOWN, FINAK_BREAST_CANCER_SDPP_SIGNATURE, BILD_E2F3_ONCOGENIC_SIGNATURE, TGACATY_UNKNOWN, ATF3_Q6, HAN_SATB1_TARGETS_DN, CCCNNGGGAR_OLF1_01, MODULE_207, AACTGGA_MIR145, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, CUI_TCF21_TARGETS_2_UP, ASGHARZADEH_NEUROBLASTOMA_POOR_SURVIVAL_DN, GEORGES_TARGETS_OF_MIR192_AND_MIR215, CERVERA_SDHB_TARGETS_2

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (2): cytoplasm (GO:0005737), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
intracellular anatomical structure	1

Protein interactions and networks

STRING

322 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FAXC	COQ3	Q9NZJ6	597
FAXC	QSER1	Q2KHR3	556
FAXC	USP45	Q70EL2	552
FAXC	FBXL4	Q9UKA2	552
FAXC	TEX9	Q8N6V9	542
FAXC	PNISR	Q8TF01	539
FAXC	TMTC2	Q8N394	521
FAXC	DSTYK	Q6XUX3	509
FAXC	NUFIP2	Q7Z417	499
FAXC	ENTHD1	Q8IYW4	454
FAXC	PRDM13	Q9H4Q3	448
FAXC	OXNAD1	Q96HP4	447
FAXC	FBF1	Q8TES7	441
FAXC	THRB	P10828	416
FAXC	WDR72	Q3MJ13	415

IntAct

6 interactions, top by confidence:

A	B	Type	Score
FAXC	FAXC	psi-mi:“MI:0915”(physical association)	0.370
FAXC	METTL15	psi-mi:“MI:0914”(association)	0.350
FAXC	POLRMT	psi-mi:“MI:0914”(association)	0.350
ARHGAP19	IFIT5	psi-mi:“MI:0914”(association)	0.350
FAXC	HAT1	psi-mi:“MI:0914”(association)	0.350

BioGRID (118): FAXC (Two-hybrid), ACADM (Co-fractionation), CCT8 (Co-fractionation), FAXC (Co-fractionation), FAXC (Co-fractionation), FAXC (Co-fractionation), DPP9 (Affinity Capture-MS), POLR1B (Affinity Capture-MS), TBC1D9 (Affinity Capture-MS), ATP12A (Affinity Capture-MS), TEX2 (Affinity Capture-MS), PLEKHG4 (Affinity Capture-MS), KIAA0391 (Affinity Capture-MS), TYW1 (Affinity Capture-MS), EVI5L (Affinity Capture-MS)

ESM2 similar proteins: A0JM23, A4IGD2, A5PKL6, A6NHR9, A6QQZ0, D3ZAT9, F1QWA8, O35099, O88741, O94952, P0CI65, P58005, Q29RL0, Q2TBQ7, Q3U213, Q3UMF9, Q4R6P7, Q4R6Y8, Q5E9N5, Q5F204, Q5HYI7, Q5I0G3, Q5IH14, Q5R5S1, Q5R9R1, Q5RL51, Q5TGI0, Q60649, Q6AZT7, Q6DDI6, Q6DDT5, Q6DEY8, Q6NXY1, Q6YXW6, Q7TNH6, Q7Z494, Q8NBP0, Q8NEC7, Q8TB36, Q94E75

Diamond homologs: D3ZAT9, F7E235, Q3UMF9, Q5TGI0, Q95RI5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

59 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	50
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1571 predictions. Top by Δscore:

Variant	Effect	Δscore
6:99291818:CAC:C	acceptor_gain	1.0000
6:99291820:CCT:C	acceptor_loss	1.0000
6:99291821:C:A	acceptor_loss	1.0000
6:99291822:T:A	acceptor_loss	1.0000
6:99291825:A:T	acceptor_gain	1.0000
6:99333557:G:GC	acceptor_gain	1.0000
6:99333560:CATT:C	acceptor_gain	1.0000
6:99333561:A:C	acceptor_gain	1.0000
6:99333563:T:C	acceptor_gain	1.0000
6:99333565:T:C	acceptor_gain	1.0000
6:99333565:T:TC	acceptor_gain	1.0000
6:99349102:CTCA:C	donor_loss	1.0000
6:99349104:CA:C	donor_loss	1.0000
6:99349105:A:AG	donor_loss	1.0000
6:99349106:C:A	donor_loss	1.0000
6:99291816:ATCAC:A	acceptor_gain	0.9900
6:99291817:TCAC:T	acceptor_gain	0.9900
6:99291818:CACC:C	acceptor_gain	0.9900
6:99291819:AC:A	acceptor_gain	0.9900
6:99291820:CC:C	acceptor_gain	0.9900
6:99291821:C:CC	acceptor_gain	0.9900
6:99291824:CAG:C	acceptor_gain	0.9900
6:99291826:G:GC	acceptor_gain	0.9900
6:99333344:GACTC:G	donor_loss	0.9900
6:99333345:AC:A	donor_loss	0.9900
6:99333346:CT:C	donor_loss	0.9900
6:99333347:T:TA	donor_loss	0.9900
6:99333348:C:CC	donor_loss	0.9900
6:99333349:A:AG	donor_loss	0.9900
6:99333350:C:CT	donor_loss	0.9900

AlphaMissense

2737 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:99281394:A:G	W334R	0.999
6:99281394:A:T	W334R	0.999
6:99281401:C:A	W331C	0.999
6:99281401:C:G	W331C	0.999
6:99281403:A:G	W331R	0.999
6:99281403:A:T	W331R	0.999
6:99281425:A:C	C323W	0.999
6:99281438:A:T	L319H	0.999
6:99291763:C:T	G294E	0.999
6:99291764:C:G	G294R	0.999
6:99291764:C:T	G294R	0.999
6:99291765:A:C	F293L	0.999
6:99291765:A:T	F293L	0.999
6:99291767:A:G	F293L	0.999
6:99291769:A:T	V292D	0.999
6:99291775:G:T	A290D	0.999
6:99323471:C:G	D266H	0.999
6:99323648:A:G	W207R	0.999
6:99323648:A:T	W207R	0.999
6:99333507:G:T	P148H	0.999
6:99342919:C:A	R127S	0.999
6:99342919:C:G	R127S	0.999
6:99342943:A:C	C119W	0.999
6:99342958:A:C	S114R	0.999
6:99342958:A:T	S114R	0.999
6:99342960:T:G	S114R	0.999
6:99281426:C:T	C323Y	0.998
6:99281438:A:C	L319R	0.998
6:99281438:A:G	L319P	0.998
6:99281447:A:G	L316P	0.998

dbSNP variants (sampled 300 via entrez): RS1000019872 (6:99298918 C>A,T), RS1000020418 (6:99324373 G>C), RS1000087251 (6:99344895 C>A), RS1000113142 (6:99281707 T>A), RS1000139750 (6:99345196 C>T), RS1000221971 (6:99306508 C>G), RS1000223705 (6:99310059 G>A,C), RS1000235668 (6:99351135 C>A), RS1000398151 (6:99300054 A>C), RS1000497670 (6:99299315 T>C), RS1000627839 (6:99326385 A>C,G), RS1000646403 (6:99273339 G>A,C), RS1000660476 (6:99344815 C>T), RS1000667948 (6:99318215 C>G,T), RS1000743842 (6:99274861 C>G,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST005839_10	Depression	3.000000e-08
GCST006041_46	Major depressive disorder	6.000000e-06
GCST006922_14	Regular attendance at a religious group	2.000000e-08
GCST007576_139	Chronotype	1.000000e-09
GCST008968_3	White coat effect (clinic systolic blood pressure minus ambulatory systolic blood pressure)	3.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0009592	social interaction measurement
EFO:0008328	chronotype measurement
EFO:0006944	systolic blood pressure change measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	2
(+)-JQ1 compound	affects expression, increases reaction, decreases expression	2
beta-lapachone	increases expression	1
butyraldehyde	decreases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
propionic acid	decreases expression	1
nickel sulfate	increases expression	1
pentanal	decreases expression	1
entinostat	decreases expression	1
abrine	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
NSC 689534	affects binding, decreases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Panobinostat	affects expression, increases reaction	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cisplatin	affects cotreatment, decreases expression	1
Copper	affects binding, decreases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Nickel	decreases expression	1
Testosterone	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	increases expression	1
Valproic Acid	decreases expression	1
Antirheumatic Agents	increases expression	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer